Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print January 10, 2007, doi:10.1212/01.wnl.0000254483.19854.ef)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Spanish Translation
Right arrow All Versions of this Article:
01.wnl.0000254483.19854.efv1
68/14/1141    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldwurm, S.
Right arrow Articles by Pezzoli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldwurm, S.
Right arrow Articles by Pezzoli, G.
Received July 28, 2006
Accepted November 13, 2006

Evaluation of LRRK2 G2019S penetrance

S. Goldwurm MD, PhD*, M. Zini MD, L. Mariani MD, PhD, S. Tesei MD, R. Miceli PhD, F. Sironi , M. Clementi , V. Bonifati MD, PhD, and G. Pezzoli MD

From Istituti Clinici di Perfezionamento (S.G., M.Z., S.T., F.S., G.P.), Parkinson Institute-Milan; Unit of Medical Statistics and Biometry (L.M., R.M.), Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; Molecular Genetics Laboratory (F.S.), Foundation "Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena," Milan; Clinical Genetic Service (M.C.), Department of Pediatrics, University of Padova, Italy; and Department of Clinical Genetics (V.B.), Erasmus MC Rotterdam, The Netherlands.


* To whom correspondence should be addressed. E-mail: goldwurm{at}parkinson.it.

Abstract--We report the results of a family-based study of LRRK2 G2019S penetrance in Parkinson disease. We studied 19 families identified through the analysis of unrelated consecutive patients. The cumulative incidence of the disease was 15% at 60 years, 21% at 70 years, and 32% at 80 years. This study provides accurate estimates of G2019S penetrance by minimizing the selection bias.




This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
S. Lesage and A. Brice
Parkinson's disease: from monogenic forms to genetic susceptibility factors
Hum. Mol. Genet., April 15, 2009; 18(R1): R48 - R59.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
D G Healy, N W Wood, and A H V Schapira
Test for LRRK2 mutations in patients with Parkinson's disease
Practical Neurology, December 1, 2008; 8(6): 381 - 385.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Marras and A. Lang
Invited Article: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain
Neurology, May 20, 2008; 70(21): 1996 - 2003.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.